Docality.com Logo
 
Dr. Ravitharan  Krishnadasan  Md image

Dr. Ravitharan Krishnadasan Md

3838 N Campbell Ave
Tucson AZ 85719
520 942-2873
Medical School: Other - 2000
Accepts Medicare: Yes
Participates In eRX: No
Participates In PQRS: No
Participates In EHR: No
License #:
NPI: 1174538995
Taxonomy Codes:
207RH0003X

Request Appointment Information

Awards & Recognitions

About Us

Practice Philosophy

Conditions

Dr. Ravitharan Krishnadasan is associated with these group practices

Procedure Pricing

HCPCS Code Description Average Price Average Price
Allowed By Medicare
HCPCS Code:38221 Description:Bone marrow biopsy Average Price:$566.00 Average Price Allowed
By Medicare:
$74.03
HCPCS Code:99205 Description:Office/outpatient visit new Average Price:$541.00 Average Price Allowed
By Medicare:
$161.83
HCPCS Code:99204 Description:Office/outpatient visit new Average Price:$428.00 Average Price Allowed
By Medicare:
$126.28
HCPCS Code:99215 Description:Office/outpatient visit est Average Price:$377.00 Average Price Allowed
By Medicare:
$106.62
HCPCS Code:99214 Description:Office/outpatient visit est Average Price:$279.00 Average Price Allowed
By Medicare:
$75.82
HCPCS Code:99233 Description:Subsequent hospital care Average Price:$289.00 Average Price Allowed
By Medicare:
$99.52
HCPCS Code:99213 Description:Office/outpatient visit est Average Price:$185.00 Average Price Allowed
By Medicare:
$49.42
HCPCS Code:99232 Description:Subsequent hospital care Average Price:$202.00 Average Price Allowed
By Medicare:
$69.38
HCPCS Code:G0364 Description:Bone marrow aspirate &biopsy Average Price:$39.00 Average Price Allowed
By Medicare:
$8.79

HCPCS Code Definitions

99205
Office or other outpatient visit for the evaluation and management of a new patient, which requires these 3 key components: A comprehensive history; A comprehensive examination; Medical decision making of high complexity. Counseling and/or coordination of care with other physicians, other qualified health care professionals, or agencies are provided consistent with the nature of the problem(s) and the patient's and/or family's needs. Usually, the presenting problem(s) are of moderate to high severity. Typically, 60 minutes are spent face-to-face with the patient and/or family.
99204
Office or other outpatient visit for the evaluation and management of a new patient, which requires these 3 key components: A comprehensive history; A comprehensive examination; Medical decision making of moderate complexity. Counseling and/or coordination of care with other physicians, other qualified health care professionals, or agencies are provided consistent with the nature of the problem(s) and the patient's and/or family's needs. Usually, the presenting problem(s) are of moderate to high severity. Typically, 45 minutes are spent face-to-face with the patient and/or family.
38221
Bone marrow; biopsy, needle or trocar
99213
Office or other outpatient visit for the evaluation and management of an established patient, which requires at least 2 of these 3 key components: An expanded problem focused history; An expanded problem focused examination; Medical decision making of low complexity. Counseling and coordination of care with other physicians, other qualified health care professionals, or agencies are provided consistent with the nature of the problem(s) and the patient's and/or family's needs. Usually, the presenting problem(s) are of low to moderate severity. Typically, 15 minutes are spent face-to-face with the patient and/or family.
G0364
Bone marrow aspiration performed with bone marrow biopsy through the same incision on the same date of service
99214
Office or other outpatient visit for the evaluation and management of an established patient, which requires at least 2 of these 3 key components: A detailed history; A detailed examination; Medical decision making of moderate complexity. Counseling and/or coordination of care with other physicians, other qualified health care professionals, or agencies are provided consistent with the nature of the problem(s) and the patient's and/or family's needs. Usually, the presenting problem(s) are of moderate to high severity. Typically, 25 minutes are spent face-to-face with the patient and/or family.
99233
Subsequent hospital care, per day, for the evaluation and management of a patient, which requires at least 2 of these 3 key components: A detailed interval history; A detailed examination; Medical decision making of high complexity. Counseling and/or coordination of care with other physicians, other qualified health care professionals, or agencies are provided consistent with the nature of the problem(s) and the patient's and/or family's needs. Usually, the patient is unstable or has developed a significant complication or a significant new problem. Typically, 35 minutes are spent at the bedside and on the patient's hospital floor or unit.
99232
Subsequent hospital care, per day, for the evaluation and management of a patient, which requires at least 2 of these 3 key components: An expanded problem focused interval history; An expanded problem focused examination; Medical decision making of moderate complexity. Counseling and/or coordination of care with other physicians, other qualified health care professionals, or agencies are provided consistent with the nature of the problem(s) and the patient's and/or family's needs. Usually, the patient is responding inadequately to therapy or has developed a minor complication. Typically, 25 minutes are spent at the bedside and on the patient's hospital floor or unit.
99215
Office or other outpatient visit for the evaluation and management of an established patient, which requires at least 2 of these 3 key components: A comprehensive history; A comprehensive examination; Medical decision making of high complexity. Counseling and/or coordination of care with other physicians, other qualified health care professionals, or agencies are provided consistent with the nature of the problem(s) and the patient's and/or family's needs. Usually, the presenting problem(s) are of moderate to high severity. Typically, 40 minutes are spent face-to-face with the patient and/or family.

Medical Malpractice Cases

None Found

Medical Board Sanctions

None Found

Referrals

NPI
Doctor Name
Specialty
Count
1386644433
Pathology
663
1750440996
Hematology/Oncology
653
1891890083
Internal Medicine
554
1043347578
Diagnostic Radiology
553
1295747335
Pathology
541
1710998844
Diagnostic Radiology
466
1366539462
Pathology
376
1578660015
Cardiovascular Disease (Cardiology)
324
1366548349
Cardiovascular Disease (Cardiology)
314
1740384130
Pathology
307
*These referrals represent the top 10 that Dr. Krishnadasan has made to other doctors

Publications

"Almost bleeding to death": the conundrum of acquired amegakaryocytic thrombocytopenia. - Case reports in hematology
Acquired amegakaryocytic thrombocytopenia (AAT) is a rare hematological disorder causing severe thrombocytopenia and bleeding. Previous in vitro studies postulated both cell-mediated suppression of megakaryocytopoiesis in early megakaryocytic progenitor cells and humoral-mediated suppression by anti-thrombopoietin antibodies as possible etiologies of AAT. Patients with AAT usually present with severe bleeding and thrombocytopenia that is unresponsive to steroids and intravenous immunoglobulin (IVIG). Although standard guidelines have not been established for management of AAT, a few case reports have indicated a response to immunosuppressive treatment. The prompt recognition of this disease entity is essential in view of the substantial risk of morbidity and mortality from excessive bleeding. We report a case of AAT successfully treated with equine antithymocyte globulin (ATG) and cyclosporine (CSP).
Heart of lymphoma: primary mediastinal large B-cell lymphoma with endomyocardial involvement. - Case reports in oncological medicine
Primary mediastinal B-cell lymphoma (PMBCL) is an uncommon aggressive subset of diffuse large B-cell lymphomas. Although PMBCL frequently spreads locally from the thymus into the pleura or pericardium, it rarely invades directly through the heart. Herein, we report a case of a young Mexican female diagnosed with PMBCL with clear infiltration of lymphoma through the cardiac wall and into the right atrium and tricuspid valve leading to tricuspid regurgitation. This was demonstrated by cardiac MRI and transthoracic echocardiogram. In addition, cardiac MRI and CT scan of the chest revealed the large mediastinal mass completely surrounding and eroding into the superior vena cava (SVC) wall causing a collar of stokes. The cardiac and SVC infiltration created a significant therapeutic challenge as lymphomas are very responsive to chemotherapy, and treatment could potentially lead to vascular wall rupture and hemorrhage. Despite the lack of conclusive data on chemotherapy-induced hemodynamic compromise in such scenarios, her progressive severe SVC syndrome and respiratory distress necessitated urgent intervention. In addition to the unique presentation of this rare lymphoma, our case report highlights the safety of R-CHOP treatment.
Overexpression of SOCS3 is associated with decreased survival in a cohort of patients with de novo follicular lymphoma. - British journal of haematology
The prognostic significance of SOCS3 protein expression was determined in de novo follicular lymphomas (FL) with t(14;18) and bcl-2 overexpression. Presentation lymph nodes from 82 FL patients for whom clinical information was available were immunohistochemically segregated into SOCS3-positive (n = 42) or -negative (n = 40) cohorts, and overall survival (OS) was analysed. SOCS3-positive FL patients had a median OS of 10 years compared with 22 years in SOCS3-negative patients (P = 0.001, log rank test). After adjusting for Follicular Lymphoma International Prognostic Index subgroups, SOCS3 overexpression remained an independent predictor of decreased OS (P < 0.001). These findings suggest that overexpression of SOCS3 may be an independent poor prognostic variable in patients with de novo FL.
Case of relentless chronic phase of chronic myeloid leukaemia. - BMJ case reports
Initial treatment of chronic phase chronic myeloid leukaemia is straightforward in today's era of tyrosine kinase inhibitors. However, managing refractory cases remain a major challenge due to the multiple factors that can influence decision-making, including medication tolerance, disease burden, mutation status, comorbidities, availability of donor, and fitness for an ablative conditioning. We report a male patient presenting with chronic phase chronic myeloid leukaemia who was treated with 5 different tyrosine kinase inhibitors either due to intolerance and/or failed response. He subsequently received 2 haploidentical haematopoietic stem cells transplants before achieving complete remission. This case highlights various treatment options, need for vigilant disease monitoring, and the possibility of complete positive response even after many lines of therapy failure.2016 BMJ Publishing Group Ltd.

Map & Directions

3838 N Campbell Ave Tucson, AZ 85719
View Directions In Google Maps

Nearby Doctors

3390 N. Campbell Ave Ste 110
Tucson, AZ 85719
520 957-7650
3390 N Campbell Ave Ste 110
Tucson, AZ 85719
520 957-7650
1609 N Warren Ave
Tucson, AZ 85719
520 267-7233
1980 E Fort Lowell Rd Suite 150
Tucson, AZ 85719
520 964-4280
3323 N Campbell Avenue Suite No 6
Tucson, AZ 85719
520 234-4303
3390 N Campbell Ave Ste 110
Tucson, AZ 85719
520 957-7650
3390 N Campbell Ave Ste 110
Tucson, AZ 85719
520 957-7650
1745 E Glenn St Apt 215
Tucson, AZ 85719
520 918-8413
1650 E Fort Lowell Rd Ste 202
Tucson, AZ 85719
520 274-4505
1609 N Warren Ave Ste 110
Tucson, AZ 85719
520 269-9245